What is NDC 31722-752?

31722-752 is the product NDC for Lamivudine, Lamivudine 100 mg/1 tablet, film coated, listed with the FDA by Camber Pharmaceuticals, Inc.. It has 4 package NDCs, shown above in 10- and 11-digit form.

Camber Pharmaceuticals, Inc., NDC labeler code 31722. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Lamivudine?

24 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Lamivudine NDC 31722-752 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)31722-752Labeler and product segments. Claims need a package NDC.

Product NDC at billing width31722-0752Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
31722-752-06	31722075206	600 TABLET, FILM COATED in 1 BOTTLE (31722-752-06)Marketed from Jan 2, 2014
31722-752-31	31722075231	10 TABLET, FILM COATED in 1 BLISTER PACK (31722-752-31)Marketed from Jan 2, 2014
31722-752-32	31722075232	100 TABLET, FILM COATED in 1 CARTON (31722-752-32)Marketed from Jan 2, 2014
31722-752-60	31722075260	60 TABLET, FILM COATED in 1 BOTTLE (31722-752-60)Marketed from Jan 2, 2014

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Lamivudine
Generic name (nonproprietary): lamivudine
Active ingredients: Lamivudine — 100 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Camber Pharmaceuticals, Inc.NDC labeler code 31722
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 203260
Marketing start: Jan 2, 2014
Listing expires: Dec 31, 2027
Other FDA classes: Nucleoside Reverse Transcriptase Inhibitors (Mechanism)
Identifiers: Product ID 31722-752_57c05c90-abd7-b7ab-e063-6394a90a93dbSPL ID 57c05c90-abd7-b7ab-e063-6394a90a93dbSPL set ID 6bd6b9da-df69-46db-813e-4e7f3bdecf95RxCUI 205328UNII 2T8Q726O95
Pharmacologic class: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N431722075206 followed by a unit qualifier and the quantity

Package 31722-0752-06. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 29, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Lamivudine tablets (HBV) are indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation [see Clinical Studies ( 14.1 , 14.2 )]. The following points should be considered when initiating therapy with lamivudine tablets (HBV): • Due to high rates of resistance development in treated patients, initiation of treatment with lamivudine tablets (HBV) should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. • Lamivudine tablets (HBV) have not been evaluated in patients co-infected with human immunodeficiency…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 31722-752

What is NDC 31722-752?: 31722-752 is the product NDC for Lamivudine, Lamivudine 100 mg/1 tablet, film coated, listed with the FDA by Camber Pharmaceuticals, Inc.. It has 4 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Lamivudine.
What is the active ingredient?: Lamivudine.
Who is the labeler?: Camber Pharmaceuticals, Inc., NDC labeler code 31722. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Lamivudine?: 24 other product NDCs are listed under this name. See all Lamivudine NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Lamivudine NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Lamivudine	Lamivudine 150 mg/1	Tablet, Film coatedOral	Coupler LLC	67046-1459	67046-1459-03
Lamivudine	Lamivudine 150 mg/1	Tablet, Film coatedOral	American Health Packaging	60687-720	60687-0720-21
Lamivudine	Lamivudine 150 mg/1	Tablet, Film coatedOral	Macleods Pharmaceuticals Limited	33342-001	33342-0001-09
Lamivudine	Lamivudine 300 mg/1	Tablet, Film coatedOral	Macleods Pharmaceuticals Limited	33342-002	33342-0002-07
lamivudine	Lamivudine 100 mg/1	Tablet, Film coatedOral	Camber Pharmaceuticals, Inc.	31722-001	31722-0001-0231722-0001-60
Lamivudine	Lamivudine 150 mg/1	Tablet, Film coatedOral	Strides Pharma Science Limited	64380-710	64380-0710-03
Lamivudine	Lamivudine 300 mg/1	Tablet, Film coatedOral	Strides Pharma Science Limited	64380-711	64380-0711-04
Lamivudine	Lamivudine 150 mg/1	TabletOral	Ingenus Pharmaceuticals, LLC	50742-623	50742-0623-60
Lamivudine	Lamivudine 300 mg/1	TabletOral	Ingenus Pharmaceuticals, LLC	50742-624	50742-0624-60
Lamivudine	Lamivudine 10 mg/mL	SolutionOral	Rising Pharma Holdings, Inc.	57237-274	57237-0274-24

All 25 Lamivudine NDCs